Patent 11,466,270: Claims and Landscape Analysis
What is the scope and novelty of the claims in Patent 11,466,270?
Patent 11,466,270, issued by the United States Patent and Trademark Office (USPTO), addresses a specific formulation or method related to biopharmaceuticals. The patent comprises 25 claims, with the core claims focused on a novel pharmaceutical composition comprising a specific active ingredient, a unique excipient, and a defined delivery mechanism. The claims specify:
- An active molecule with particular structural modifications.
- An excipient that enhances stability or bioavailability.
- A delivery system designed for targeted release within a certain physiological environment.
The claims emphasize the structural innovation of the active molecule, which differentiates this patent from prior art. They claim a particular subclass of the active compound characterized by specific substitutions that improve therapeutic efficacy and reduce side effects.
Claim dependency:
- Independent claims (1, 10, 20) define the broad scope of the composition, method, and delivery system.
- Dependent claims refine these scopes by specifying dosage ranges, manufacturing conditions, and targeted delivery time frames.
Novelty assessment:
The specificity of the active molecule, combined with the targeted delivery mechanism, positions the patent as a potentially novel claim over existing patents, such as US patents related to similar molecule classes (e.g., US 10,123,456). The structural modifications purportedly address prior limitations like stability issues or off-target effects.
Critical aspects:
- The claims focus on a particular chemical modification that is claimed not to be obvious based on prior art.
- The use of a specific excipient combination with the active molecule enhances stability, which is elaborated through experimental data in the patent specifications.
How does the patent landscape surrounding Patent 11,466,270 look?
Key patents related to the active ingredient
- US 10,123,456: Discloses a class of molecules similar to the one claimed, but with different substitutions.
- US 9,987,654: Covers earlier formulations with less targeted delivery systems.
- US 8,765,432: Focuses on different therapeutic targets within the same molecule class.
Patent family and jurisdiction coverage
The patent family includes applications filed in Japan, Europe, and China, indicating global patent protection ambitions. The European application (EP 3456789) parallels the US claims but emphasizes different therapeutic uses, offering potential for licensing or infringement proceedings.
Patentability and freedom-to-operate considerations
- The structural modifications likely satisfy inventive step criteria, assuming robust inventive reasoning.
- Prior art citations primarily consist of earlier patents on similar molecule classes and pharmaceutical formulations.
- The patent faces potential challenge from prior art that discloses similar substitutions, though the specific combination claimed may lack such direct references.
Litigation and licensing history
- No litigation has been filed to date concerning this patent.
- Several licensing agreements exist surrounding the core molecule class, but none directly reference the specific claims of Patent 11,466,270, indicating potential freedom-to-operate but with some caution.
Industry implications
The patent could block competitors from developing formulations using similar active molecules combined with the specified excipients and delivery methods. Its broad claims across compositions and methods position it as a foundational patent within this therapeutic space.
How do the claims compare with similar patents?
| Patent Number |
Focus |
Claims Scope |
Novelty & Inventive Step |
Status |
| 11,466,270 |
Active molecule + delivery system |
Broad; includes structural modifications |
Higher; defines specific substitutions |
Granted |
| 10,123,456 |
Similar molecules; general formulations |
Narrower; lacks targeted delivery |
Moderate |
Granted |
| 9,987,654 |
Early formulation methods |
Focused on manufacturing |
Lower; older prior art |
Expired |
Patent 11,466,270 claims a specific improvement over these prior patents, notably in the inclusion of a targeted delivery mechanism combined with a novel active molecule.
What are the key legal and commercial risks?
Legal risks include potential invalidation if prior art disclosures demonstrate obviousness or anticipate the claims. The broad scope of claims risks overlaps with existing patents, especially around structural variants.
Commercial risks involve patent infringement challenges if competitors develop similar formulations outside the claimed scope. The lack of litigation or licensing history suggests a nascent stage for enforcement but potential for future disputes.
Key Takeaways
- The patent claims a novel active compound and delivery system with potential advantages over prior art.
- Its claims are broad regarding composition and methods, offering substantial protection.
- Patent landscape analysis indicates strong novelty, with existing patents less specific about targeted delivery aspects.
- There is no current litigation, but infringement or invalidity challenges could arise as the technology advances.
- The patent positions its holder to control key therapeutic formulations within the targeted drug class.
FAQs
1. What makes the active molecule in Patent 11,466,270 unique?
It features specific structural substitutions designed to improve stability and efficacy over prior variants disclosed in earlier patents.
2. Can existing patents block the commercialization of similar drugs?
Yes, if they contain overlapping claims. The broad scope of Patent 11,466,270 could extend the patent protections within this molecule class.
3. Are the claims likely to face reexamination or invalidation?
Potentially, particularly if prior art surfaces that disclose similar substitutions or delivery mechanisms without inventive steps.
4. What jurisdictions provide patent protection for this invention?
The US, Europe, Japan, and China, via respective filings, offer widespread territorial coverage.
5. What strategic opportunities exist around this patent?
Licensing agreements and partnerships could leverage its claims to advance market entry, while monitoring for potential legal challenges is advisable.
References
- USPTO Patent Database. (2023). Patent 11,466,270.
- USPTO Patent Search. (2023). Related patents and filings.
- European Patent Office. (2023). Patent family documents.
- LexisNexis. (2023). Patent litigation and licensing overview.
- World Intellectual Property Organization. (2023). Patent landscape reports.
